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ABSTRACT: Catechol diether compounds have nanomolar antiviral and enzymatic activity against HIV with reverse transcriptase 
(RT) variants containing K101P, a mutation that confers high-level resistance to FDA-approved non-nucleoside inhibitors efavirenz 
and rilpivirine. Kinetic data suggests that RT (K101P) variants are as catalytically fit as wild-type and thus can potentially increase 
in the viral population as more antiviral regimens include efavirenz or rilpivirine. Comparison of wild-type structures and a new 
crystal structure of RT (K101P) in complex with a leading compound confirms that the K101P mutation is not a liability for the 
catechol diethers while suggesting that key interactions are lost with efavirenz and rilpivirine.  
Despite the success of highly active antiretroviral therapy 
(HAART) for the treatment of HIV,1-3 resistance and subopti-
mal pharmacological properties of antiviral agents continues 
to limit the efficacy of current drug regimens.4,5 Due to the 
error prone nature of HIV replication,6,7 the predominant 
mechanism of resistance involves the selection of mutations in 
target enzymes HIV protease, integrase, and reverse transcrip-
tase (RT).8-10 The majority of anti-HIV drugs target RT by 
binding to the polymerase site (nucleoside RT inhibitors or 
NRTIs) or an allosteric site known as the non-nucleoside bind-
ing pocket (non-nucleoside RT inhibitors or NNRTIs). Re-
sistance-associated mutations (RAMs) within or near the non-
nucleoside binding pocket reduce the potency of first genera-
tion NNRTIs such as efavirenz.9 Rilpivirine represents a new 
class of flexible diarylpyrimidne (DAPY) inhibitors that main-
tain activity against several RT resistant variants with K103N, 
Y181C, Y188L, and L100I mutations.11-13 As more combina-
tion treatments such as Complera14 include rilpivirine in an-
tiretroviral regimens, less frequent variants of RT may emerge 
that contain mutations at the K101 position. These mutations 
include K101E, K101H, and K101P amino acid changes.5,15-18 
While the K101E mutation emerges in the viral population at 
greater frequency, K101P confers much greater resistance.5 
Specifically, RT variants with the K101P mutation are up to 
243-fold less susceptible to rilpivirine and >50-fold less sus-
ceptible to efavirenz,10 a common NNRTI included in HAART 
regimen Atripla.14
 
Moreover, rilpivirine has additional phar-
macological limitations in terms of poor solubility and viro-
logical failure associated with dose-limiting cardiotoxicity.19,20 
As efavirenz and rilpivirine are widely used in HAART regi-
mens, very few options regarding NNRTIs are available for 
patients suffering from virologic failure due to minority RAMs 
such as K101P in RT.  
Figure 1. Potency (EC50) and cytotoxicity (CC50) values for 
efavirenz, rilpivirine, and compounds 1-3 determined using a 
single-round infectivity assay. Solubility measurements are 
reported (in µg/ml) for each respective compound. EC50 values 
are reported in nM; CC50 values are reported in µM. 
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  To design new inhibitors that are effective against several 
variants of RT while retaining good pharmacological proper-
ties, we have implemented a multi-disciplinary approach to 
examine mutations such as K101P that confer resistance to 
rilpivirine. Previously we reported several kinetic, mechanis-
tic, and structural studies on RT and a new class of non-
nucleoside inhibitors known as the catechol diethers.21-25 In 
this study, we evaluated some of the leading catechol diether 
compounds, in terms of potency and solubility, against a panel 
of HIV strains containing RT variants with K101P, K103N, 
and Y181C mutations using a single round infectivity assay. 
Results from the assay reveal that our leading catechol diether 
compounds maintain potency for RT K101P variants, while 
rilpivirine resistance is reaffirmed as in earlier reported stud-
ies.5,10,15,17, 26 
 In order to understand the effects of the K101P mutation, 
kinetic data for the RT (K101P) enzyme was evaluated and 
compared to the wild-type, RT (WT). We also obtained a co-
crystal structure of RT (K101P) with a catechol diether, com-
pound 3, to evaluate the binding interactions in the non-
nucleoside pocket. To our knowledge, this is the first study 
that kinetically and structurally characterizes RT with the 
K101P mutation with regards to rilpivirine resistance and in-
hibitor development.  
 In pursuit of an inhibitor that maintains affinity against a 
panel of RT variants, a single infectivity assay was used to 
evaluate compounds 1, 2, 3, efavirenz, and rilpivirine for anti-
viral activity against a panel of RT variants (Figure 1). Com-
pounds 1-3 were selected due to their high potency and good 
aqueous solubility (Figure 1).21,23,25 As reported in several 
studies,11,12,17 rilpivirine has an excellent resistance profile spe-
cifically for variants with K103N, Y181C, and L100I muta-
tions.  In the panel of variants tested in this study, rilpivirine 
retains potency for variants with K103N, and Y181C muta-
tions in the low to mid-nanomolar range; this is in agreement 
with previously determined antiviral data.11,12,21 However, the 
K101P mutation drastically affects rilpivirine potency, causing 
an 88-fold increase in EC50 compared to the wild-type (WT 
X4) strain. The K101P mutation also affects the potency of 
NNRTI efavirenz in which there is an observed 58-fold in-
crease in EC50 compared to WT X4. Interestingly, both the 
rigid structure of efavirenz and more flexible DAPY structure 
of rilpivirine lose potency for RT variants containing the 
K101P mutation. 
 In evaluating the catechol diether compounds, 1-3 main-
tain efficacy for HIV variants containing the K101P mutation 
in the low nanomolar range with essentially no loss of potency 
compared to WT X4. In an improvement over the results from 
an MTT assay used previously,21, 23, 25 RT variants with Y181C 
are also susceptible to 1-3 in the low nanomolar range. Com-
pounds 1-2 are less effective against variants containing the 
K103N mutation, whereas 3 retains potency 4-fold greater 
than rilpivirine. Our data reaffirms observations from several 
assays5,15,17,27 that reveal RT variants with K101P are resistant 
to rilpivirine. Thus, we were interested in characterizing the 
RT (K101P) enzyme kinetically and structurally to understand 
the effects of the K101P mutation, rilpivirine resistance, and 
the molecular mechanism by which catechol diether com-
pounds retain potency.   
 RT variants with the K101P mutation are in low frequen-
cy in the HIV viral population compared to high frequency 
variants containing Y181C and K1013N mutations.5,10 Howev-
er, we were compelled to characterize RT (K101P) with re-
gards to enzyme fitness to perhaps understand why it appears 
less frequently in the viral population. To assess enzyme ca-
talysis as an indication of fitness for RT (K101P) and RT 
(WT), we used pre-steady state kinetics to determine rates of 
deoxynucleotide incorporation, kpol (Table 1) and misincorpo-
ration (Table 2) opposite dT in the template as well as the 
dNTP affinity, Kd, and efficiency (kpol /Kd,). In terms of incorpo-
ration, RT (WT) and RT (K101P) utilize the correct incoming 
nucleotide (dATP) with similar catalytic efficiencies. These 
results suggest that, despite its low viral frequency, the K101P 
mutation does not compromise the polymerization capabilities 
of RT, and that the RT (K101P) enzyme is just as catalytically 
fit as the RT (WT) enzyme. In terms of misincorporation, RT 
(K101P) is more efficient in incorporating an incorrect deox-
ynucleotide (dGTP) than RT (WT) (Tables 1 and 2). More 
strikingly, there is a 12-fold reduction in RT (K101P) fidelity 
compared to RT (WT) (Table 2). The K101P mutation seems 
to enhance misincorporation and this results in an RT enzyme 
that is more error prone and likely to generate new mutations 
in the viral genome.  









RT (WT) 2.2 ± 0.9 14 ± 2 6.4 ± 2.7 
RT (K101P) 9.2 ± 0.8  25.3 ± 0.4 2.8 ± 0.2 










780 ± 470 0.11 ± 
0.02 
1.4 x 10-4 ± 





530 ± 110 0.39 ± 
0.04 
7.4 x 10-4 ± 




1  2  3  
RT 
(WT) 







2.2 ± 0.5 2.1 ± 0.4 1.9 ± 0.3 
Table 1. Kinetic characterization of correct incorporation of 
dATP for RT (WT) and RT (K101P). 
Table 2. Kinetic characterization of dGTP misincorporation oppo-
site dT for  RT (WT) and RT (K101P).  
Table 3. Inhibition data (IC50 in nM) for rilpivirine and com-
pounds 1-3 determined using Pico Green fluorescence assay. 
a
















 Fidelity is defined as the ratio of efficiencies for correct/incorrect 
incorporation for RT (WT) and RT (K101P), respectively.  
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  To complement the antiviral data, we used a PicoGreen 
fluorescence assay to examine the inhibition of reverse tran-
scription. IC50 values were determined for rilpivirine and com-
pounds 1-3 using methods described previously.22,28 Activity 
and inhibition assays were determined for both RT (WT) and 
RT (K101P) enzymes. IC50 values for both RT (WT) and RT 
(K101P) are similar to the EC50 values determined for the WT 
X4 and K101P strains in the single infectivity assay. Com-
pounds 1-3 have IC50 values in the low nanomolar range for 
both RT variants. For compounds 1-3, there is a minimal fold-
change in potency ranging from 0.6-1.8, whereas the potency 
of rilpivirine is reduced by 67-fold for RT (K101P) (Table 3). 
Compelled by the antiviral and enzyme inhibition data, struc-
tural analysis was pursued to understand binding interactions 
and to determine a potential mechanism of resistance caused 
by the K101P mutation. 
 Wild-type structures for RT in complex with efavirenz, 
rilpivirine, and all three catechol diether compounds 1-3 are 
currently available.11,22,24,25,29 In analyzing the wild-type struc-
tures, we examined the binding interactions of efavirenz, rilpi-
virine, and compound 3 (our most potent representative of the 
catechol diether inhibitors) specifically with K101 (Figure 
2C). In both efavirenz and rilpivirine structures (Figure 2A 
and 2B), a salt bridge is apparent between E138 (p51 subunit 
of RT) and K101 (p66 subunit of RT). This salt bridge is lo-
cated at the rim of the binding pocket for both efavirenz and 
rilpivirine. Interestingly, this salt bridge seems to stabilize the 
positioning of the K101 backbone in order to make either 2 
hydrogen bonds with efavirenz (Figure 2A) or 1 hydrogen 
bond with rilpivirine (Figure 2B). In contrast, compound 3 
binds further away from both K101 and E138 and the salt 
bridge is weaker (in terms of distance of ion pairs). Compound 
3 does not form any hydrogen bonds with K101 and is farther 
away from the rim of the pocket (Figure 2C).  Based on this 
analysis, we hypothesized that the amino acid change from 
lysine to proline at position 101 would affect crucial interac-
tions with efavirenz and rilpivirine, while not affecting com-
pounds 1-3.  
 A co-crystal structure of the RT (K101P):3 complex re-
veals that the compound can accommodate the non-nucleoside 
binding pocket and bind in a similar orientation as in the RT 
(WT) structure (Figure 3A).  In fact, the residues within the 
RT (WT) with RT (K101P) binding pocket superimpose with 
an rmsd of only 0.419 Å. P101 does not appear to be interact-
ing with compound 3 since the compound binds deeper into 
the tunnel region of the pocket (Figure 3B). As speculated by 
the analysis of the wild-type structures, K101 does not interact 
with 3, but instead makes several van der Waals interactions 
with residues in the pocket such as P95, V106, V108, V179, 
Y188, F227, W229, L234, and Y318. This suggests that the 
proline substitution does not affect the binding of 3 and the 
other catechol diether compounds. As confirmed by the antivi-
ral and inhibition data, the K101P mutation reduces efavirenz 
and rilpivirine susceptibility. In agreement with this data we 
were not able to co-crystallize either of these inhibitors with 
RT (K101P), likely due to the low binding affinity between 
the NNRTI binding pocket and the inhibitors. By extension of 
the structural analysis, the reliance of K101 for salt bridge 
stabilization and direct backbone hydrogen bonding may con-
tribute to the high level resistance observed for rilpivirine and 
efavirenz with K101P RT variants.  
 In parallel to the single-infectivity assays, we have also 
examined compounds 2 and 3 against RT variants with E138K 
and E138K/M184V RAMs in an MTT assay for antiviral ac-
tivity (Table S2). Compounds 2 and 3 are extraordinarily po-
tent for E138K, with EC50 values of 2.8 nM and 900 pM, re-
spectively. For RT variants with E138K/M184V, similar EC50 
values are observed with 2.2 nM (2) and 750 pM (3). Com-
plementary to our analysis of the RT (K101P) structure, the 
antiviral data for E138K variants suggest that disruption of the 
E138-K101 salt bridge has little effect on catechol diether 
potency. Interestingly, E138K is not only a key residue for salt 
bridge stabilization, as observed in the efavirenz and rilpi-
virine RT (WT) structures, but it is also the most common 
RAM identified in patients receiving rilpivirine combination 
therapies.30   
Figure 2. Comparison of K101 (orange) interactions for RT (WT) in complex with (A) efavirenz (PDB Code: 1FK9), (B) rilpivirine 
(PDB code: 2ZD1), and (C) compound 3 (PDB Code: 4MFB). Compound 3 binds farther away from the E138-K101 salt bridge and 
does not interact with K101. 
Figure 3. (A) Superposition of the RT (WT):3 (teal, 3=pink) 
and RT (K101P):3 (purple, 3=yellow) complexes. Compound 
3 adopts the same orientation in both RT (WT) and RT 
(K101P) structures. (B) Representation of the RT (K101P):3 
structure with respect to the location of P101 and E138. A salt 
bridge between E138 and P101 cannot be formed in the RT 
(K101P) structure suggesting that this lost interaction would 
most likely affect the binding of efavirenz and rilpivirine. 
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  In summary, the catechol diether compounds were evalu-
ated against a panel of RT variants. Compounds 1-3 emerge as 
potent inhibitors of HIV strains containing RT (K101P) vari-
ants and the enzyme inhibition data correlates well with this 
discovery. In characterizing the enzyme kinetically, we found 
that the RT (K101P) variant is just as catalytically fit as RT 
(WT) but has reduced fidelity. However, this data only de-
scribes the catalytic fitness of RT (K101P) relative to RT 
(WT) and does not account for viral replication capacity. Fu-
ture experiments can be used to evaluate viral fitness31 in the 
context of RT (K101P) and whether this directly correlates 
with enzymatic catalytic fitness. Despite its low frequency to 
date in clinically isolated strains, RT (K101P) variants have 
high-level resistance to both efavirenz and rilpivirine, the two 
major NNRTIs used in HAART combination therapies. Anal-
ysis of the current wild-type structures for efavirenz, rilpi-
virine, and 3 reveal that the latter inhibitor does not rely on a 
key hydrogen bond with K101. A crystal structure of RT 
(K101P) in complex with 3 reveals that the P101 mutation 
does not interact with 3 nor does this mutation affect com-
pound binding relative to the wild-type structure. The catechol 
diether compounds can be developed as effective non nucleo-
side inhibitors targeting RT variants with minority RAM 
K101P, in addition to E138K, in the case of increasing treat-
ment failure of DAPY inhibitors such as rilpivirine due to 
high-level resistance.  
ASSOCIATED CONTENT  
Supporting Information. Materials and methods, data collec-
tion and refinement statistics for the RT (K101P):3 structure, 
and electron density maps. This material is available free of 
charge via the internet at http://pubs.acs.org. 
 
The RT (K101P):3 complex is deposited as an entry in the 
Protein Data Bank with accession code 5C42. 
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